More on BMY

- Summary
- Chart
- Profile
- Historical


- Earnings (+64.1% Growth)
- Ratings (3.3 Score)
- Holders
- Dividends (0.8% Yield)
- FDA Archive


Income Statement
Balance Sheet
Cash Flow Statement

Upcoming Events

- Earnings (10/27/16)


- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks

BMY Balance Sheet

Click line-items for a historical chart and %
Current Assets:
Cash and cash equivalents 2.93B
Marketable securities 1.72B
Receivables 5.62B
Inventories 1.44B
Deferred income taxes
Prepaid expenses and other 588M
Total Current Assets 12.3B
Property, plant and equipment 4.6B
Goodwill 6.88B
Other intangible assets 1.38B
Deferred income taxes 3.39B
Marketable securities 3.28B
Other assets 1.01B
Total Assets 32.83B
Current Liabilities:
Short-term borrowings 155M
Accounts payable 1.5B
Accrued expenses 4.88B
Deferred income 1.18B
Accrued rebates and returns
U.S. and foreign income taxes payable 164M
Dividends payable
Total Current Liabilities 7.89B
Pension, postretirement, and postemployment liabilities
Deferred income 586M
U.S. and foreign income taxes payable 896M
Other liabilities 1.81B
Long-term debt 6.58B
Total Liabilities 17.75B
Commitments and contingencies (Note 14) 0
Bristol-Myers Squibb Company Shareholders' Equity:
Preferred stock, $2 convertible series, par value $1 per share: Authorized 10 million shares; issued and outstanding 5,268 in 2011 and 5,269 in 2010, liquidation value of $50 per share 0
Common stock, par value of $0.10 per share: Authorized 4.5 billion shares; 2.2 billion issued in both 2011 and 2010 221M
Capital in excess of par value of stock 1.59B
Accumulated other comprehensive loss -2.8B
Retained earnings 32.71B
Less cost of treasury stock - 500 million common shares in 2011 and 501 million in 2010 -16.8B
Total Bristol-Myers Squibb Company Shareholders' Equity 14.92B
Noncontrolling interest 160M
Total Equity 15.08B
Total Liabilities and Equity 32.83B